Balchem (FRA:BL9B) Cyclically Adjusted Revenue per Share: €23.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BL9B Balchem Corp FRA:BL9B
93 GF Score
Price €138.00
GF Value €149.73
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Balchem Cyclically Adjusted Revenue per Share?

Balchem FRA:BL9B 93 Cyclically Adjusted Revenue per Share is €23.99 as of Mar. 2026. GuruFocus rates FRA:BL9B with a GF Score™ of 93/100 and a GF Value™ of €149.73 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Balchem's adjusted revenue per share for the three months ended in Mar. 2026 was €7.253. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €23.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Balchem's average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Balchem was 22.80% per year. The lowest was 6.90% per year. And the median was 13.40% per year.

As of today (2026-07-23), Balchem's current stock price is €138.00. Balchem's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €23.99. Balchem's Cyclically Adjusted PS Ratio of today is 5.75.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Balchem was 8.70. The lowest was 4.65. And the median was 6.16.


Balchem  (FRA:BL9B) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Balchem's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=138.00/23.99
=5.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Balchem was 8.70. The lowest was 4.65. And the median was 6.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Balchem Cyclically Adjusted Revenue per Share Related Terms


Balchem Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Balchem's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Balchem Cyclically Adjusted Revenue per Share Chart

Balchem Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.59 21.27 22.74 25.43 24.44

Balchem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.11 22.76 23.01 24.44 23.99

FRA:BL9B vs PRM, SXT, CBT: Cyclically Adjusted Revenue per Share Comparison

For the Specialty Chemicals subindustry, Balchem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Balchem Cyclically Adjusted PS Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Balchem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Balchem's Cyclically Adjusted PS Ratio falls into.


FRA:BL9B
93GF Score
Balchem Corp FRA:BL9B
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Balchem Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Balchem's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=7.253/330.2130*330.2130
=7.253

Current CPI (Mar. 2026) = 330.2130.

Balchem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.875 241.018 5.309
201609 3.859 241.428 5.278
201612 4.166 241.432 5.698
201703 4.000 243.801 5.418
201706 4.065 244.955 5.480
201709 3.922 246.819 5.247
201712 4.165 246.524 5.579
201803 4.049 249.554 5.358
201806 4.320 251.989 5.661
201809 4.080 252.439 5.337
201812 4.433 251.233 5.827
201903 4.275 254.202 5.553
201906 4.388 256.143 5.657
201909 4.437 256.759 5.706
201912 4.615 256.974 5.930
202003 4.855 258.115 6.211
202006 4.741 257.797 6.073
202009 4.573 260.280 5.802
202012 4.569 260.474 5.792
202103 4.775 264.877 5.953
202106 5.144 271.696 6.252
202109 5.152 274.310 6.202
202112 5.762 278.802 6.825
202203 6.399 287.504 7.350
202206 6.929 296.311 7.722
202209 7.622 296.808 8.480
202212 6.776 296.797 7.539
202303 6.700 301.836 7.330
202306 6.581 305.109 7.122
202309 6.634 307.789 7.117
202312 6.458 306.746 6.952
202403 6.758 312.332 7.145
202406 6.661 314.175 7.001
202409 6.594 315.301 6.906
202412 6.985 315.605 7.308
202503 7.063 319.799 7.293
202506 6.777 322.561 6.938
202509 6.994 324.800 7.111
202512 6.968 324.054 7.100
202603 7.253 330.213 7.253

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €23.99 mean?
Balchem (FRA:BL9B) has a Cyclically Adjusted Revenue per Share of €23.99 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Balchem and its competitors.
Is Balchem's Cyclically Adjusted Revenue per Share too high?
Balchem's current Cyclically Adjusted Revenue per Share is €23.99. Overall, Balchem has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Balchem's Cyclically Adjusted Revenue per Share compare to PRM and SXT?
Balchem's Cyclically Adjusted Revenue per Share of €23.99 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Chemicals company?
A good Cyclically Adjusted Revenue per Share depends on the Chemicals industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Balchem and its competitors. Balchem's current Cyclically Adjusted Revenue per Share is €23.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balchem stock overvalued right now?
Based on GuruFocus' analysis, Balchem (FRA:BL9B) is currently considered Fairly Valued. The stock's GF Value™ is €149.73, compared to a current price of €138.00 — trading 7.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €23.99. Balchem's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Balchem (FRA:BL9B), the current Cyclically Adjusted Revenue per Share is €23.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Balchem (FRA:BL9B) Overvalued in 2026?

Based on GuruFocus' analysis, Balchem stock appears to be undervalued. The current stock price of €138.00 is trading 7.8% below its estimated GF Value™ of €149.73. GuruFocus considers Balchem to be Fairly Valued.

Key valuation signals for FRA:BL9B:

  • Cyclically Adjusted Revenue per Share: €23.99
  • GF Value™: €149.73 vs. price of €138.00 (7.8% below fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the FRA:BL9B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Balchem Business Description

Other Exchanges BCPC:USA
Address 5 Paragon Drive, Montvale, NJ, USA, 07645
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
93GF Score

Get the complete analysis for FRA:BL9B

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€138.00
Price
€149.73
GF Value